147490-72-0

Upstream product

• 160905-66-8 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine 
• 98-88-4 benzoyl chloride 
• 115012-52-7 1-(2-Fluorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine 
• 1054642-81-7 N-[2-Oxo-1-((2R,3R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-trimethylsilanyloxy-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1,2-dihydro-pyrimidin-4-yl]-benzamide 
• 69304-42-3 3',5'-O-[(1,1,3,3-tetraisopropyl)-1,3-disiloxanediyl]cytidine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 65-46-3 CYTIDINE 
• 13089-48-0 N₄-benzoylcytidine 

Downstream Products

• 147490-75-3 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-5'-O-(9-phenylxanthen-9-yl)cytidine 
• 160905-74-8 4-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>cytidine 
• 115012-46-9 1-(2-fluorophenyl)piperidin-4-one 
• 13089-48-0 N₄-benzoylcytidine 
• 160905-78-2 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)cytidine 
• 160905-68-0 4-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)cytidine 
• 147490-79-7 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-5'-O-(9-phenylxanthen-9-yl)cytidine 3'-<(2-cyanoethyl)-N,N-diisopropylphosphoroamidite> 

Relevant academic research and scientific papers

Novel Solid-phase Synthesis of Branched Oligoribonucleotides, including a Substrate for the RNA Debranching Enzyme

An effective new route for synthesizing branched oligoribionucleotides in the solid phase in the 5' to 3' direction has been developed.This required the synthesis of reversed monomers, viz. protected nucleoside 5'-phosphoramidites bearing 2'-O-Fpmp and 3'

Use of the 1-(2-Fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) Protecting Group in the Solid-Phase Synthesis of Oligo- and Poly-ribonucleotides

An approach to the solid-phase synthesis of oligo- and poly-ribonucleotides is described.The synthetic strategy involves the use of building blocks in which two acid-labile groups, 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) and 9-phenylxanthen-9-yl